Table 1 Clinical and pathological characteristics of patient cohorts used to assess prognostic significance of EMAT subtypes
Factor | METABRIC (n = 562) No. (%) | GSE11121 (n = 200) No. (%) | NKI295 (n = 151) No. (%) |
|---|---|---|---|
Age, years | |||
 < 50 | 20.8 | 23.2 | 84.1 |
 > 50 | 78.8 | 76.8 | 15.9 |
 Unknown | 0.4 | 100 |  |
Tumor size, cm | |||
 < 2 | 39.5 | 49.5 | 54.3 |
 2–5 | 57.7 | 49 | 45.7 |
 > 5 | 2.3 | 1.5 |  |
 Unknown | 0.5 | 0 | 0 |
Tumor grade | |||
 Low | 8.5 | 14.5 | 22.5 |
 Intermediate | 42.3 | 68 | 30.5 |
 High | 42.3 | 17.5 | 47.0 |
 Unknown | 6.8 | 0 | 0 |
ER | |||
 Negative | 17.3 | 23.2 | 27.8 |
 Positive | 78.8 | 76.8 | 72.2 |
 Unknown | 3.9 | 0 | 0 |
PR | |||
 Negative | 43.8 | 41.8 |  |
 Positive | 56.2 | 58.2 |  |
 Unknown | 0 | 0 | 100 |
HER2 | |||
 Negative | 80.2 | 89.0 |  |
 Positive | 19.4 | 0.11 |  |
 Unknown | 0.4 | 0 | 100 |
Adjuvant therapy | |||
 Chemotherapy | 7.1 | N/A | 4.0 |
 Hormonal therapy | 47.9 | N/A | 4.0 |
 Radiation therapy | 54.4 | N/A | 40.4 |
PAM50 status | |||
 Luminal A | 44.1 | 27 | 31.8 |
 Luminal B | 19.9 | 23.5 | 25.2 |
 HER2 | 7.5 | 12.5 | 16.6 |
 Basal-like | 15.3 | 17.5 | 18.5 |
 Normal-like | 13 | 18 | 7.9 |
EMAT status | |||
 EMAT1 | 19.4 | 22.5 | 17.2 |
 EMAT2 | 45.7 | 31 | 35.1 |
 EMAT3 | 26 | 29.5 | 27.8 |
 EMAT4 | 8.9 | 17 | 19.9 |